Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
12 evidence topics · 13 sources
ODT versus capsule: relative bioavailability study design (MM-120-101)
ODT versus capsule: published abstract results
ODT versus capsule: company analysis of pharmacokinetic parameters, March 2024
Formulation rationale stated by the sponsor
Food effect study of DT120 ODT: design
“Phase 1 PK Food Effect (n = 64)” (opens the source at this quote in a new tab)
“Cohort 1: 100-μg ODT fasted vs high-fat meal” (opens the source at this quote in a new tab)
“Cohort 2: 100-μg ODT fasted vs low-fat meal” (opens the source at this quote in a new tab)
“Open-label, crossover in healthy volunteers” (opens the source at this quote in a new tab)
Food effect study of DT120 ODT: treatment-emergent adverse events by cohort
| Measure | DT120 ODT + high-fat meal (n = 31) | DT120 ODT + low-fat meal (n = 28) |
|---|---|---|
| Any TEAE | “31 (100.0)” | “28 (100.0)” |
| TEAE leading to treatment withdrawal | “1 (3.2)” | “2 (7.1)” |
| Mild | “24 (77.4)” | “22 (78.6)” |
| Moderate | “7 (22.6)” | “5 (17.9)” |
| Severe | “0” | “1 (3.6)” |
| Any related TEAE | “31 (100.0)” | “28 (100.0)” |
Food effect study of DT120 ODT: UK research ethics and registry records
“REC reference 24/WA/0003” (opens the source at this quote in a new tab)
“Date of REC Opinion 22 Mar 2024” (opens the source at this quote in a new tab)
“Phase I trial MM-120-102” (opens the source at this quote in a new tab)
“ref: 24/WA/0003” (opens the source at this quote in a new tab)
“Phase I study in 32 healthy volunteers” (opens the source at this quote in a new tab)
“Non randomised study” (opens the source at this quote in a new tab)
“Completion date 29/08/2024” (opens the source at this quote in a new tab)
Food effect: regulatory expectation for oral psychedelic drugs
Absorption, peak concentration, and half-life of oral LSD
“Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/mL (1.6-2.0) and 3.4 ng/mL (3.0-3.8) after the administration of 85 and 170 μg LSD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal concentrations were achieved on average after 1.7 h.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Elimination half-lives were 3.7 h (3.4-4.1) and 4.0 h (3.6-4.4), for 85 and 170 μg LSD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LSD exhibited dose-proportional pharmacokinetics and first-order elimination kinetics and dose-dependent duration and intensity of subjective effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Geometric mean (95% confidence interval) maximum plasma concentration values of 1.3 (1.2–1.9) and 3.1 (2.6–4.0) ng/mL were reached 1.4 and 1.5 h after administration of 100 and 200 µg LSD, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The plasma half-life was 2.6 h (2.2–3.4 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral LSD presented dose-proportional pharmacokinetics and first-order elimination up to 12 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absolute oral bioavailability and bioequivalence of LSD base and tartrate
“We used a randomized, double‐blind, placebo‐controlled, five‐period crossover design in 20 healthy participants to investigate an ethanolic drinking solution of LSD base, a watery drinking solution of LSD tartrate, a rapid dissolvable tablet of LSD base, an intravenous formulation of LSD tartrate, and corresponding placebos.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All oral formulations were bioequivalent, with the ethanolic base solution as a reference.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The absolute bioavailability of oral LSD was 80% and similar for all tested formulations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, dosing with LSD base and tartrate can be considered bioequivalent with high and similar oral bioavailability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism and urinary excretion
“Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LSD is extensively metabolized and shows dose-proportional urinary recovery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cytochrome P450 enzymes in LSD metabolism
“CYP2D6, 2E1, and 3A4 significantly contributed to the formation of nor-LSD, and CYP1A2, 2C9, 2E1, and 3A4 were significantly involved in the formation of O-H-LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To conclude, human liver microsomes converted only small amounts of LSD to nor-LSD and O-H-LSD but several CYPs significantly contributed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote